Our findings indicate that these discrepancies are conceivably attributable to (a) the utilization of the LNCaP PCa cell line because it contains the T877A AR mutation and (b) the limited range of mostly pharmacological genistein concentrations used in most of these studies. The gene discussed is AR; the disease is posterior cortical atrophy.